How AI and Biomarkers Will Drive Progress in Longevity Science

How to Cite

Dmitry. (2019). How AI and Biomarkers Will Drive Progress in Longevity Science. American Journal of Translational Medicine, 3(3), 96–103. Retrieved from


Aging is the single biggest risk factor for developing many diseases including Alzheimer's, Parkinson's, cancer, osteoporosis, and cardiovascular disease. Few breakthroughs would make as profound an impact on humanity as delaying aging. Curing aging would have a greater impact on society than curing cancer. Longevity Science is driven by the convergence of multiple distinct technological and biomedical sectors and sub-sectors including geroscience, geriatrics, regenerative medicine, precision medicine, digital health, and advanced technologies. Longevity scientists seek to end the threat of age-related disease for this and future generations by developing a comprehensive understanding of the biology of aging itself. Science is showing that chronological aging is inevitable but biological aging is malleable. AI and biomarkers will accelerate real-world implementations of Longevity Science leading to a paradigm shift from Precision Medicine to Precision Health. AI and biomarkers will be the central factors driving progress of Longevity Science. In the short term, deep diagnostic and prognostic technologies enabled by AI will empower people to maintain an optimal state of health until the final stages of life. In the long term, the most promising areas of Longevity Science are those that intervene at the root causes of aging to delay the onset of age-related disease. (Am J Transl Med 2019. 3:96-103).